Eminyakeni yamuva nje, ukwelashwa kokukhuluphala kanye nesifo sikashukela sohlobo 2 kuye kwaba nenqubekelaphambili yenguquko. Ukulandela ama-agonists e-GLP-1 receptor (isb, i-Semaglutide) nama-agonists amabili (isb, i-Tirzepatide),I-Retatrutide(LY3437943), ai-agonist kathathu(i-GLP-1, GIP, kanye nama-glucagon receptors), ikhombise ukusebenza ngendlela engakaze ibonwe. Ngemiphumela emangalisayo ekunciphiseni isisindo kanye nokwenza ngcono i-metabolic, kuthathwa njengokwelashwa okungaba khona kwezifo ze-metabolic.
Indlela Yokwenza
-
Ukusebenza kwe-GLP-1 receptor: Ithuthukisa ukukhiqizwa kwe-insulin, icindezela ukudla, ibambezela ukuphuma kwesisu.
-
GIP receptor activation: Yandisa imiphumela yokwehlisa i-glucose ye-GLP-1, ithuthukisa ukuzwela kwe-insulin.
-
Ukusebenza kwe-Glucagon receptor: Ithuthukisa ukusetshenziswa kwamandla kanye ne-fat metabolism.
I-synergy yalawa ma-receptors amathathu ivumela i-Retatrutide ukuthi idlule izidakamizwa ezikhona kukho kokubili ukwehla kwesisindo nokulawulwa kwe-glycemic.
Idatha Yokuhlolwa Komtholampilo (Isigaba II)
Phakathi kuIsivivinyo seSigaba II esineziguli ezingama-338 ezikhuluphele/ezikhuluphele, I-Retatrutide ibonise imiphumela ethembisa kakhulu.
Ithebula: Ukuqhathaniswa kwe-Retatrutide vs. Placebo
| Umthamo (mg/ngeviki) | Ukunciphisa Isisindo Esimaphakathi (%) | Ukwehliswa kwe-HbA1c (%) | Imicimbi Emibi Ejwayelekile |
|---|---|---|---|
| 1 mg | -7.2% | -0.9% | Isicanucanu, ukuhlanza okuncane |
| 4 mg | -12.9% | -1.5% | Isicanucanu, ukuphelelwa ukudla |
| 8 mg | -17.3% | -2.0% | Ukungakhululeki kwe-GI, isifo sohudo esincane |
| 12 mg | -24.2% | -2.2% | Isicanucanu, ukuphelelwa ukudla, ukuqunjelwa |
| I-Placebo | -2.1% | -0.2% | Alukho ushintsho olubalulekile |
Ukubonakala Kwedatha (Ukuqhathanisa Ukunciphisa Isisindo)
Ibha shadi elilandelayo libonisaisilinganiso sokunciphisa isisindokumithamo ehlukene ye-Retatrutide uma kuqhathaniswa ne-placebo:
Isikhathi sokuthumela: Sep-16-2025